D.E. Shaw & Co
INBX icon

D.E. Shaw & Co’s Inhibrx INBX Stock Holding History

D.E. Shaw & Co’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.18M Hold
17,600
– – ﹤0.01% 3322
2025
Q4 		$1.39M Buy
+17,600
New +$1.2M ﹤0.01% 3323

Other funds holding INBX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

D.E. Shaw & Co's INBX Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Inhibrx (INBX) stake by 37% in Q1 2026, selling an estimated $3.31M and leaving 77,437 shares worth $5.21M. The position accounts for ﹤0.01% of the portfolio, ranked #2140.

D.E. Shaw & Co first reported a position in INBX in Q3 2025 and has held it in 3 quarters since. The position peaked at $9.65M in Q4 2025. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

  • D.E. Shaw & Co held 77,437 shares of Inhibrx worth $5.21M as of Q1 2026.
  • D.E. Shaw & Co sold 44,664 Inhibrx shares in Q1 2026, an estimated $3.31M.
  • Inhibrx made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #2140 holding.
  • D.E. Shaw & Co first reported a position in Inhibrx in Q3 2025 and has held it in 3 quarters since.
  • D.E. Shaw & Co's Inhibrx position peaked at $9.65M in Q4 2025.
  • 135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.